PHILADELPHIA, May 26 /PRNewswire/ -- Premier Research Group Limited, the international pharmaceutical services company, announces the appointment of Hal Ward, R.Ph., PharmD as Executive Director, Global Pharmacovigilance. In this position, he will lead the global pharmacovigilance team ensuring the delivery of quality medical and safety services.
Hal brings to Premier Research a wealth of experience in global safety monitoring, clinical and post marketing surveillance, and drug safety compliance and training programs. For the past three years, he has served as the Executive Director and Global Head of Drug Safety at Covance Late Stage Development Services Clinical Division where he had overall responsibility for the Drug Safety organization, including accurate and timely regulatory reporting, implementation of quality assurance and quality improvement plans, implementation of training and SOP programs, measurement of productivity and workload efficiency, and client satisfaction. Prior to joining Covance in 2006, Hal led the Global Medical Affairs Compliance Training team at Wyeth. He also led the Drug Safety Training team at Wyeth's Global Safety Surveillance and Epidemiology Division. Prior to that, he led the gastrointestinal team at Astra Merck's Product Safety and Epidemiology division.
"We are very pleased to have Hal joining our team in this important role," said James Ottinger, Vice President, Global Consulting and Compliance. "His expertise and proven leadership will strengthen our team and help us expand our pharmacovigilance services to meet the evolving needs of our clients."
About Premier Research
Premier Research is a leading global solutions-driven CRO committed to therapeutic focus and operational expertise to deliver clinical trial services of the highest quality for biopharmaceutical and medical device companies. They are leaders in clinical research for analgesia, CNS, oncolo
|SOURCE Premier Research Group Limited|
Copyright©2009 PR Newswire.
All rights reserved